Investor Connect - Episode 294 - Gary Madsen of ProTransit Nanotherapy

In this episode, Hall welcomes Gary Madsen of ProTransit Nanotherapy. Gary Madsen, Ph.D., has over 30 years of experience in developing and launching biotechnology products in a wide variety of markets at companies of various sizes. He spent 17 years at Abbott Laboratories in product support, new product development and business development. His expertise in product commercialization has helped him to success building new technologies; today that has led him to a promising new technology -- nanoparticle drug delivery.

Gary advises that potential investors in biotechnology make sure that the technology is workable, scalable, and that it has good supporting data beyond just slick advertising. Gary explains some of the technology behind nanoparticle drug delivery, and its potential applications. In addition, Gary touches on why skincare is a good entry point for new technology, as well as some of the technical challenges in scaling production. Finally, Gary outlines some of things that ProTransit has done to set themselves up for success as they pursue additional applications for their technology.